I wonder what this means for whole-genome sequencing. If we sequence the entire genome of a patient, and we discover this mutation, would we have to pay Myriad?

I wonder what this means for whole-genome sequencing. If we sequence the entire genome of a patient, and we discover this mutation, would we have to pay Myriad? Or, are we not allowed to look in that gene-region? Or just not allowed to tell the patient? What about the next gene? I know that this is really just a patent on a specific genetic test, but what about the next gene, and the next one... This will only get messier before it (hopefully) gets better.